Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: A single institutional experience

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 4029-4033

  Yoshino, Kiyoshi ^a   Hiramatsu, Kosuke ^a   Enomoto, Takayuki ^a   Fujita, Masami ^a   Ueda, Yutaka ^a   Kimura, Toshihiro ^a   Kobayashi, Eiji ^a   Kiyohara, Yumiko ^a   Tsutsui, Tateki ^a   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin resistance; Gemcitabine; Recurrent ovarian cancer; Salvage chemotherapy; Taxane resistance

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; LOW DRUG DOSE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY ADENOCARCINOMA; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; URTICARIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BRIDGED COMPOUNDS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TAXOIDS;

EID: 84866978501     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U: Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95(Suppl 1) : S161-192, 2006.
2. Ozols RF: The current role of gemcitabine in ovarian cancer. Semin Oncol 28: 18-24, 2001.
3. Plunkett W, Huang P, Searcy CE and Gandhi V: Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23: 3-15, 1996.
4. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR and Cass CE: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58 : 4349-4357, 1998.
5. Lund B, Hansen OP, Theilade K, Hansen M and Neijt JP: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J National Cancer Institute 86: 1530-1533, 1994.
6. Matsuo K, Lin YG, Roman LD and Sood AK: Overcoming platinum resistance in ovarian carcinoma. Expert Opinion Investigational Drugs 19: 1339-1354, 2010.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 : 228-247, 2009.
8. National Cancer Institute: Common Terminology Criteria for Adverse Events v4.0. http://ctep.cancer.gov/reporting/ctc.html
9. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL Jr.: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389-393, 1991.
10. Harries M and Gore M: Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol 3: 537-545, 2002.
11. Silver DF and Piver MS: Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum. American J Clinical Oncol 22: 450-452, 1999.
12. Lorusso D, Ferrandina G, Fruscella E, Marini L, Adamo V and Scambia G: Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives. Int J Gynecol Cancer 15: 1002-1013, 2005.
13. Watanabe Y, Koike E, Nakai H, Etoh T and Hoshiai H: Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer. International journal of clinical oncology/Japan Society of Clinical Oncology 13 : 345-348, 2008.
14. Cesano A, Lane SR, Poulin R, Ross G and Fields SZ: Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol 15 : 1233-1238, 1999.
15. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88: 2584-2589, 2000.
16. Enomoto T, Kuragaki C, Yamasaki M, Sugita N, Ohtsuki Y, Ikegami H, Matsuzaki N, Yamada T, Wakimoto A and Murata Y: Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 22: 447, 2003.
17. Takano M, Sugiyama T, Yaegashi N, Sakuma M, Suzuki M, Saga Y, Kuzuya K, Kigawa J, Shimada M, Tsuda H, Moriya T, Yoshizaki A, Kita T and Kikuchi Y: Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer 18: 937-942, 2008.
18. Yoshino K, Enomoto T, Fujita M, Ueda Y, Kimura T, Kobayashi E and Tsutsui T: Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients. International journal of clinical oncology / Japan Society of Clinical Oncology 2011.
19. Ferrandina G, Legge F, Mey V, Nannizzi S, Ricciardi S, Petrillo M, Corrado G and Scambia G: A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge. Cancer Chemother Pharmacol 60 : 459-461, 2007.
20. Komiyama S, Nakamura M, Murakami I, Kuwabara Y, Kurahashi T, Tanaka K and Mikami M: A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine. Arch Gynecol Obstet 278: 565-568, 2008.